▶주메뉴 바로가기

▶본문 바로가기

THE INVESTOR
November 21, 2018
Big Reunion

Bio & Medicine

Panagene gets approval for STD test kit

  • PUBLISHED :October 26, 2018 - 14:36
  • UPDATED :October 26, 2018 - 14:36
  • 폰트작게
  • 폰트크게
  • facebook
  • twitter
  • sms
  • print

[THE INVESTOR] Korean biotechnology firm Panagene said on Oct. 26 that the country’s health regulator has granted approval for sale of its diagnostics kit for sexually transmitted diseases.

The product -- PANARealTyper TM STD Detection kit -- detects 12 types of pathogenic bacteria causing STDs by a single probe. 




The company has applied its technology named PANARealTyper, which is a multiplex melting curve analysis using fluorescence labeled PNA probe, to the kit.

In 2016, Panagene launched a diagnostic tool for human papillomavirus using the same technology.

The Ministry of Food and Drug Safety’s approval is a milestone for the company which is seeking to expand its product portfolio to go beyond cancer diagnosis, the Daejeon-based firm said.

“Starting with the STD kit, we will pursue market expansion here and overseas by releasing new products,” a company official said.

Last year, Panagene introduced liquid biopsy lung cancer diagnosis kit called PANAMutyper R EGFR that enables the detection of as little as 0.1 percent mutant allele, seeking to replace painful tumor tissue extract tests.

By Park Han-na (hnpark@heraldcorp.com)   

  • facebook
  • twitter
  • sms
  • print

EDITOR'S PICKS